Business Context and Reporting Period
This Form 8-K reports on the 2019 Annual Meeting of Shareholders for Second Sight Medical Products, Inc. (Note: The request metadata lists "Vivani Medical, Inc.", but the filing text explicitly identifies the registrant as Second Sight Medical Products, Inc.). The meeting was held on June 4, 2019, in Los Angeles, California. The report was filed on June 5, 2019.
Key Financial Metrics
This filing is a Current Report regarding shareholder voting results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of three proposals submitted to shareholders. A total of 115,704,477 shares were represented at the meeting, constituting a quorum.
- Proposal 1 (Election of Directors): Shareholders elected all five nominees to the Board of Directors.
- Will McGuire: 86,082,462 For
- William J. Link: 85,926,724 For
- Aaron Mendelsohn: 85,968,760 For
- Gregg Williams: 85,778,488 For
- Matthew Pfeffer: 86,064,643 For
- Proposal 2 (Increase in Authorized Shares): Shareholders approved an amendment to the Restated Articles of Incorporation to increase authorized common stock from 200,000,000 to 300,000,000 shares.
- For: 108,559,132
- Against: 3,974,325
- Abstentions: 745,915
- Proposal 3 (Ratification of Auditors): Shareholders ratified the appointment of Gumbiner Savett Inc. as the independent registered public accounting firm for the year ending December 31, 2019.
- For: 114,509,466
- Against: 788,181
- Abstentions: 406,830
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the administrative results of the shareholder vote.
Important Facts for Investors to Verify
- Confirm the registrant name is Second Sight Medical Products, Inc. (trading symbol EYES), not Vivani Medical, Inc.
- Verify the impact of the increased authorized share count (300 million) on potential future dilution.
- Review the full Proxy Statement filed on April 25, 2019, for detailed biographies of the elected directors and the rationale for the auditor ratification.
- Note that no financial performance data is available in this specific 8-K filing.